Bonum Therapeutics, Inc.
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $27.0Mattributed |
|---|---|
| Latest round | Funding round, $27.0M, 2026-04-03attributed |
| Founded | 2021 |
| Headquarters | SEATTLE, WA |
| Industry | biotechnology |
| Stage | unknown |
| Website | bonumtherapeutics.com |
Antibody-controlled therapeutics with dual-binding antibodies that stay inactive until they encounter their target, focused on regulated cytokines. Targets oncology with extensions into autoimmune, metabolic, and pain indications. Differentiated by activity-on-binding antibody chemistry rather than payload chemistry.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-04-03 | Funding round | $27.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $27.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $27.0M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | bonumtherapeutics.com, read 2026-05-07 |
| Description | self-reported | bonumtherapeutics.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $27.0M, 2026-04-03 → Funding round, $27.0M, 2026-04-03, sec-edgar, No document URL on file | Latest round | seed, $27.0M, 2026-04-03 → Funding round, $27.0M, 2026-04-03 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes